ARTICLE IN ACADEMIC JOURNALS
NO | DETAILS OF ARTICLE IN ACADEMIC JOURNALS |
---|---|
1. |
Hepatitis C virus core antigen as alternative diagnostic algorithm for active hepatitis C virus infection among haemodialysis population: Cost implications
2021
Author(s) : Fatiha Hana Shabaruddin Source : Nephrology DOI : https://doi.org/10.1111/nep.13862 |
2. |
Estimating the Population Size of People Who Inject Drugs in Malaysia for 2014 and 2017 Using the Benchmark-Multiplier Method.
2020
Author(s) : Fatiha Hana Shabaruddin Source : Substance Use and Misuse DOI : https://doi.org/10.1080/10826084.2019.1708943 |
3. |
Assessing adherence and persistence to non-vitamin K antagonist oral anticoagulants (NOACs) among patients with atrial fibrillation in tertiary-care referral centers in Malaysia
2020
Author(s) : Fatiha Hana Shabaruddin Source : Journal of Pharmacy and BioAllied Sciences |
4. |
A Stepwise Approach to a National Hepatitis C Screening Strategy in Malaysia to Meet the WHO 2030 Targets: Proposed Strategy, Coverage, and Costs.
2019
Author(s) : Rosmawati Binti Mohamed,Fatiha Hana Shabaruddin Source : Value in Health Regional Issues |
5. |
Hepatitis C elimination by 2030 in Malaysia: an achievable goal?
2019
Author(s) : Rosmawati Binti Mohamed,Fatiha Hana Shabaruddin Source : Journal of Virus Eradication |
6. |
Generic Cost-Effectiveness Models: A Proof of Concept of a Tool for Informed Decision-Making for Public Health Precision Medicine.
2019
Author(s) : Fatiha Hana Shabaruddin Source : Public Health Genomics |
7. |
Risk of upper gastrointestinal adverse events in Malaysian rheumatic patients on long-term non-steroidal anti-inflammatory drugs
2018
Author(s) : Sanjiv A/l K. Mahadeva,Fatiha Hana Shabaruddin Source : International Journal of Clinical Rheumatology DOI : 10.4172/1758-4272.1000182 |
8. |
Projections of the Healthcare Costs and Disease Burden due to
Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018-204
2018
Author(s) : Fatiha Hana Shabaruddin Source : Appl Health Econ Health Policy |
9. |
Clinical Characteristics Of Patients With Chronic Hepatitis C Infection At Initial Presentation To Tertiary Care In An Asian Middle-Income Country. Southeast Asian Journal of Tropical Medicine and Public Health 49(5): z (ISI-cited publication)
2018
Author(s) : Fatiha Hana Shabaruddin Source : Southeast Asian Journal of Tropical Medicine and Public Health |
10. |
Is BRCA Mutation Testing Cost Effective for Early Stage Breast Cancer Patients compared to Routine Clinical Surveillance? The case of an upper middle-income country in Asia
2018
Author(s) : Fatiha Hana Shabaruddin,Woo Yin Ling Source : Applied Health Economics and Health Policy |
11. |
Clinical and economic implications of upper gastrointestinal adverse events in Asian rheumatological patients on long-term non-steroidal anti-inflammatory drugs
2018
Author(s) : Fatiha Hana Shabaruddin Source : International Journal of Rheumatic Diseases |
12. |
Is Universal HLA-B*15:02 Screening a Cost-Effective Option in an Ethnically-Diverse Population? A Case Study of Malaysia.
2017
Source : British Journal of Dermatology DOI : 10.1111/bjd.15498 |
13. |
Economic evaluations of personalized medicine: existing challenges and current developments
2015
Author(s) : Fatiha Hana Shabaruddin Source : Pharmacogenomics and Personalized Medicine |
14. |
Projections of the current and future disease burden of hepatitis C virus infection in Malaysia. PLoS One 10(6):e0128091. doi:10.1371/journal.pone.0128091
2015
Author(s) : Fatiha Hana Shabaruddin |
15. |
Chapter 18 Evaluating the Cost-Effectiveness of Pharmacogenomics in Clinical Practice in the Handbook of Personalized Medicine: Advances in Nanotechnology, Drug Delivery, and Therapy
2014
Author(s) : Fatiha Hana Shabaruddin Source : the Handbook of Personalized Medicine: Advances in Nanotechnology, Drug Delivery, and Therapy (edited by Dr. Ioannis S. Vizirianakis, Aristotle University of Thessaloniki, Greece) Publisher: Pan Stanford Publishing Pte. Ltd. ISBN 978-981-4411-19-6 |
16. |
Shabaruddin FH, Chen LC, Elliott RA, Payne K (2013) A systematic review of utility values for chemotherapy-related adverse events. Pharmacoeconomics 31(4):277-288
2013
Author(s) : Fatiha Hana Shabaruddin |
17. |
Cost-effectiveness analysis in pharmacogenomics
2010
Author(s) : Fatiha Hana Shabaruddin Source : Pharmacogenomics |
18. |
Reply: Guesstimates are not good enough for
determining
what is happening in routine care.
2010
Author(s) : Fatiha Hana Shabaruddin Source : British Journal of Cancer |
19. |
Understanding chemotherapy treatment pathways of
advanced colorectal cancer patients to inform an
economic evaluation in the United Kingdom.
2010
Author(s) : Fatiha Hana Shabaruddin |
RESEARCH COLLABORATOR
GRANT | PROGRESS | STATUS |
---|